戻る Agenda
Session 6 Track A: Improving Access: Aligned Health Canada/Health Technology Assessment (HTA) Reviews
Session Chair(s)
Loretta Del Bosco
Director, Regulatory Affairs Quality Assurance Operations
AbbVie Corporation, Canada
Improving access to drugs and devices for Canadian patients by improving the overall regulatory review is at the core of the Health Canada R2D2 (Regulatory Review of Drugs and Devices) initiative. One of the key mechanisms is the alignment of Health Canada and Health Technology Assessment (HTA) reviews. Starting with a pilot in 2017 and full implementation in 2019, this session will provide the perspective of various Stakeholders (Health Canada, HTA, Industry) as they relate to this new and exciting topic.
Learning Objective : At the conclusion of this session, participants should be able to:- Understand the new Health Canada/Health Technology Assessment (HTA) review process
- Understand some of the benefits, opportunities and challenges of the new review process as they pertain to the Regulator, Health Technology Assessor and Industry
Speaker(s)
Aligned reviews between Health Canada (HC) and Health Technology Assessment organizations (HTAs)
Kelly Robinson, MSc
Health Canada, Canada
Director General, Marketed Health Products Directorate
Industry Perspectives: Aligned Reviews Between Health Canada (HC) and Health Technology Assessment Organization (HTAs)
Tharany Ganesh
AstraZeneca Canada Inc., Canada
Head, Regulatory Affairs
Speaker
Trevor Richter, PhD
CADTH, Canada
Director of Pharmaceutical Reviews